Get startedLog in
    Picture of Samyang Biopharm logo

    0120G0 — Samyang Biopharm Income Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Samyang Biopharm, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2025
    December 31st
    Period Length:12 M
    Source:Annual Audited Accounts
    Standards:
    IFRS
    Status:Final
    Revenue
    Total Revenue28,594
    Cost of Revenue
    Gross Profit14,570
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Total Operating Expenses25,903
    Operating Profit2,691
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes2,917
    Provision for Income Taxes
    Net Income After Taxes2,237
    Net Income Before Extraordinary Items
    Net Income2,237
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income2,237
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS301
    Dividends per Share